menu search

ETNB / 89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of C

89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of C
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data from the Phase 2 ENTRIGUE study in severe hypertriglyceridemia (SHTG) will be presented at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology to be held March 4-6, 2023 in New Orleans. Read More
Posted: Feb 21 2023, 08:00
Author Name: GlobeNewsWire
Views: 092140

ETNB News  

89bio's Low Price Presents An Opportunity

By Seeking Alpha
October 26, 2023

89bio's Low Price Presents An Opportunity

89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive more_horizontal

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

By GlobeNewsWire
October 17, 2023

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and more_horizontal

Why Shares of 89bio Plummeted on Tuesday

By The Motley Fool
October 10, 2023

Why Shares of 89bio Plummeted on Tuesday

89bio is a clinical-stage biotech company. It focuses on treatments for liver and cardiometabolic diseases. more_horizontal

89bio earns ‘Buy' rating in initial coverage on positive prospects for NASH therapeutic

By Proactive Investors
August 28, 2023

89bio earns ‘Buy' rating in initial coverage on positive prospects for NASH therapeutic

Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target, representing an upside of about 117.5% from th more_horizontal

89bio, Inc.: A Big Bet On NASH

By Seeking Alpha
August 10, 2023

89bio, Inc.: A Big Bet On NASH

89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock surged after top-li more_horizontal

89bio shares rise as analysts see improved outlook for NASH treatments

By Market Watch
June 13, 2023

89bio shares rise as analysts see improved outlook for NASH treatments

Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the more_horizontal

89BIO (ETNB) Just Overtook the 20-Day Moving Average

By Zacks Investment Research
May 29, 2023

89BIO (ETNB) Just Overtook the 20-Day Moving Average

89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB crossed a more_horizontal

89bio: Great Prospects After Excellent Phase 2 Data

By Seeking Alpha
May 28, 2023

89bio: Great Prospects After Excellent Phase 2 Data

ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now. more_horizontal


Search within

Pages Search Results: